Pacira announces two-year efficacy data on PCRX-201

Pacira (PCRX) BioSciences announced new data demonstrating its locally administered gene therapy candidate, PCRX-201, provided sustained improvements in knee pain, stiffness, and function for up to two years following a single local administration in patients with mild, moderate, as well as severe osteoarthritis of the knee. The data was presented during a poster session at the 2025 Osteoarthritis Research Society International, OARSI, World Congress in Incheon, South Korea, on Friday, April 25, and Saturday, April 26. Improvements in pain, stiffness and function from baseline were shown across both cohorts at all three doses and severity levels over the full 104-week study period; they were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index pain score, the stiffness score, and Knee Injury and Osteoarthritis Outcome Score. Patients in the corticosteroid -pretreated cohort achieved greater benefits than the first cohort. Improvement was observed across all severity subgroups with the greatest improvement observed among individuals with K/L grade 2 osteoarthritis of the knee.